<DOC>
	<DOCNO>NCT01002924</DOCNO>
	<brief_summary>This extension protocol subject complete allowed duration participation Endocyte-sponsored clinical trial EC145 ( vintafolide ) continue evidence clinical benefit ( stable disease well ) time complete participation study .</brief_summary>
	<brief_title>Extension Study EC145 ( Vintafolide ) Subjects Enrolled Previous Study With EC145 ( MK-8109-010 )</brief_title>
	<detailed_description>This extension protocol subject complete allowed duration participation Endocyte-sponsored clinical trial EC145 continue evidence clinical benefit ( stable disease well ) time complete participation study . Following confirmation eligibility , subject receive intravenously-administered EC145 dose 2.5 mg. Dosing occur Monday , Wednesday , Friday week 1 3 4-week cycle . No therapy administer week 2 4 . Subjects randomize non-EC145-containing treatment arm EC145 trial eligible study .</detailed_description>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vinca Alkaloids</mesh_term>
	<criteria>Must receive prior treatment EC145 within context Endocytesponsored , IRBapproved clinical trial . Disease ( i.e. , cancer ) consider `` stable '' last evaluation participate previous EC145containing study . `` Stable '' define progression disease per standard criterion ( RECIST , etc ) . Stable disease may indicate previously attain complete partial tumor shrinkage progress per standard criterion . No 10 week elapse since last evaluation `` stable disease '' . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Must recover ( baseline/stabilization ) prior EC145associated acute toxicity . Adequate bone marrow reserve , hepatic , renal function . Negative serum pregnancy test woman childbearing potential Willingness practice contraceptive method men woman childbearing potential . Pregnancy . Development secondary malignancy require treatment . Symptomatic central nervous system ( CNS ) metastasis . History receive investigational treatment systemic therapy direct control cancer since subject 's last dose parent EC145 study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Phase II</keyword>
	<keyword>Lung</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>extension</keyword>
	<keyword>EC145</keyword>
	<keyword>Prior exposure EC145</keyword>
</DOC>